Source: Sanoski CA, Bauman
JL. The Arrhythmias. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells
BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic
Approach. 8th ed. http://accesspharmacy.com/content.aspx?aid=7972803.
Accessed June 30, 2012.
- Supraventricular arrhythmia characterized by extremely
rapid (atrial rate of 400–600 beats/min) and disorganized
atrial activation resulting in irregularly irregular pulse (120–180
- Predominant mechanism is reentry, usually associated with
organic heart disease causing atrial distention (e.g., ischemia
or infarction, hypertensive heart disease, valvular disorders).
- Prevalence in United States, 0.4–1%; increases
- Prevalence expected to increase to 12–15 million
Americans by 2050.
- Lifetime risk for AF in persons at least 40 years of age estimated
to be 1 in 4.
- Rapid heart rate
- Worsening symptoms of heart failure (shortness of breath,
- Sign: Irregularly irregular pulse.
- Embolic stroke potential complication of AF.
Means of Confirmation
- Electrocardiogram (ECG) shows irregularly irregular supraventricular
rhythm with no discernible, consistent atrial activity (P waves);
ventricular response usually 120–180 beats/min.
- Atrial flutter
- Atrial tachycardia
- Atrioventricular nodal reentry tachycardia (AVNRT)
- Multifocal atrial tachycardia
- Paroxysmal supraventricular tachycardia
- Wolff-Parkinson-White syndrome
- Restore sinus rhythm.
- Prevent thromboembolic complications.
- Prevent further recurrences.
- Evaluate need for acute treatment (usually with drugs
that slow ventricular rate).
- Consider methods to restore sinus rhythm, considering risks
involved (e.g., thromboembolism).
- Consider ways to prevent long-term complications (e.g., recurrent
Algorithm for the treatment of atrial fibrillation (AF)
and atrial flutter. (BB, β-blocker; CCB, calcium
channel blocker [i.e., verapamil or diltiazem];
DCC, direct-current cardioversion.) aIf AF <48 hours,
anticoagulation prior to cardioversion is unnecessary; may consider
transesophageal echocardiogram (TEE) if patient has risk factors
for stroke. bAblation may be considered for patients who
fail or do not tolerate one or more antiarrhythmic drugs (AADs). cChronic
antithrombotic therapy should be considered in all patients with
AF and risk factors for stroke regardless of whether or not they
remain in sinus rhythm. Reprinted with permission from Wells BG,
DiPiro JT, Schwinghammer TL, et al. Pharmacotherapy Handbook. 8th
ed. New York: McGraw-Hill, 2012.
- Direct-current cardioversion (DCC) indicated to restore
sinus rhythm immediately in new-onset AF with signs/symptoms
of hemodynamic instability (e.g., severe hypotension, angina, pulmonary
- Control ventricular rate if patient hemodynamically stable
with drugs that slow conduction and increase AV node refractoriness.
- IV β-blockers (propranolol, metoprolol,
esmolol), diltiazem, or verapamil first-line in patients with normal
- Avoid IV diltiazem and verapamil and use IV β-blockers
with caution if left ventricular ejection fraction (LVEF) ≤40%.
- IV digoxin or amiodarone first-line for patients with exacerbation
of HF symptoms.
- IV amiodarone for patients who are ...
Log In to View More
If you don't have a subscription, please view our individual subscription options below to find out how you can gain access to this content.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
AccessPharmacy Full Site: One-Year Subscription
Connect to the full suite of AccessPharmacy content and resources including 30+ textbooks such as Pharmacotherapy: A Pathophysiologic Approach and Goodman & Gilman's The Pharmacological Basis of Therapeutics, high-quality videos, images, and animations, interactive board review, drug and herb/supplements databases, and more.
Pay Per View: Timed Access to all of AccessPharmacy
24 Hour Subscription $34.95
48 Hour Subscription $54.95
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.